Exploring Value: Novel Elements for Breakthrough Treatments

Value assessments are commonplace, adopted by healthcare systems to ensure their budgets are spent optimally. Given the important role they play in managing access to treatments, it is surprising that there is no common understanding of what constitutes value from the perspective of patients, society, and payers.

Breakthrough treatments offering new sources of value that are not currently considered by healthcare systems have only exacerbated this problem. For example, most gene therapies target serious conditions, which have substantial burden on patient’s families and caregivers, and offer new scientific pathways, which can accelerate the discovery of other treatments. These are sources of value not considered in traditional value assessments. This may limit patient access to the most innovative and valuable treatments, and could lead to a misallocation of precious healthcare resources.

It’s time for a frank debate.

Are current value frameworks fit for purpose in a world of gene therapies and curative treatments? How can value assessment be expanded to adequately capture new sources of value that matter to patients, society and payers?

A coherent value framework could illuminate the key benefits generated by innovative treatments and could structure a dialogue around payers’ willingness to pay for them.

Join us for the first OHE Masterclass of 2021 where OHE’s thought leaders and international experts will discuss both established and novel elements of value, including the practical and policy challenges facing companies advocating their adoption.

The Masterclass will end by considering how these arguments resonate with payers and HTA decision makers, as well as how multi-dimensional value measurement could be incorporated into existing and future value assessments.

To understand the enhanced value flower, the case for and against expanding the value definition, and how decision-makers can capture broader value elements, this Masterclass is not to be missed.

Full details and booking available here.

2021 THEME

With its devastating and far-reaching consequences, the pandemic has made clear that health and wealth are inextricably interlinked. The rapid development and introduction of new interventions to fight COVID-19 has also demonstrated that the value of healthcare interventions go far beyond narrowly defined patient benefits.

What is the real value of a highly effective vaccine for COVID-19? What wouldn’t a society pay to rid itself of the virus?

Whilst the broader value of treatments and vaccines are acknowledged at the height of the pandemic, it is critical that in the post-pandemic recovery period, that health systems invest in interventions that create the greatest value.

The 2021 Masterclass Series will take attendees through the journey of exploring value from multiple perspectives, providing tools to identify consolidated and novel sources of value, and generate compelling evidence to demonstrate them.

Whilst value assessments are necessary to ensure that healthcare expenditure is optimal, there is also a need for a common understanding of what constitutes value, capturing what matters most to patients, society, and payers.

“Demonstrating Value: evolving with innovation” will explore this lively technical and policy debate, where the evolving and sometimes challenging nature of innovative interventions is not always matched by the value assessment paradigms applied by country decision-makers.

OHE’s 2021 Masterclass may be virtual but its excellence will be real. Join OHE experts and a faculty of international thought-leaders in this stimulating and insightful series on Demonstrating Value.


  • To gain a deep-dive on theory and real-world evidence on the current debate on the value of innovative interventions to patients, healthcare systems and society, and anticipate future developments
  • To discuss and understand opportunities and barriers for the incorporation of broader sources of value which matter the most to patients and society, in terms of payers and decision-makers acceptability and evidence requirements
  • To understand the optimal approaches and solutions to improve patients, health systems and industry outcomes in areas of high unmet need such as rare diseases



Tuesday, 30 March 2021